[Jackie07]

Happened to see an abstract about the treatment of Her2-positive breast cancer [Notice the statement in the middle of the paragraph: "HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis" (Not sure if it's been posted before) Herceptin is a monoclonal 'antibody',and KADCYLA® (ado-trastuzumab emtansine = T-DM1) http://www.kadcyla.com/ is the new ‘antibody chemotherapy conjugate’]:

Breast. 2013 Dec 18. pii: S0960-9776(13)00300-7. doi: 10.1016/j.breast.2013.11.011. [Epub ahead of print]
Treatment of HER2-positive breast cancer.
Figueroa-Magalhães MC1, Jelovac D1, Connolly RM1, Wolff AC2.
Author information
Abstract
The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ∼15% of breast cancer patients and was identified a quarter century ago as a marker of poor prognosis. By 1998, antibody therapy targeting the HER2 pathway was shown to demonstrably improve progression-free and overall survival in metastatic disease, and in 2005 evidence of improvement in disease-free and overall survival from the first generation of trastuzumab adjuvant trials became available. However, not all patients with HER2 overexpression benefit from trastuzumab. Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy that will soon complete accrual. HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis, and recent guidance by the US Food and Drug Administration suggests that pathologic response to HER2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting. An adjuvant trial of trastuzumab in patient whose tumors express normal levels of HER2 and trials of single/dual HER2-targeting without chemotherapy are also ongoing. In this article, we review the current data on the therapeutic management of HER2-positive breast cancer.